Excellent — here’s **Vecuronium**, a key non-depolarising neuromuscular blocker, presented in your structured anaesthesia–ICU learning format with both molecular and clinical depth.
---
# 1) Receptor-level action → clinical effects
**Class:** *Aminosteroid, non-depolarising neuromuscular blocker (NDNMB).*
**Primary receptor action:**
* **Competitive antagonist** at **nicotinic acetylcholine receptors (nAChR)** at the **neuromuscular junction (NMJ)**.
* Competes with acetylcholine (ACh) for the α-subunits of the nAChR, preventing ion channel opening → no depolarisation → **flaccid paralysis**.
**Additional receptor/system effects:**
* **No effect on muscarinic receptors** → **no tachycardia or bronchospasm.**
* **No histamine release** → minimal hypotension or flushing.
* **No autonomic ganglion blockade.**
* Slight central nicotinic receptor effect if high doses (clinically insignificant).
**Clinical consequences:**
* Smooth, predictable paralysis with **stable haemodynamics.**
* Ideal for **cardiac surgery, ICU ventilation, and neuro cases**.
* **Reversible** by acetylcholinesterase inhibitors (e.g., neostigmine) or **sugammadex** (specific binding reversal).
---
# 2) Vial strength, preparation & basic pharmacokinetics (+ disadvantages)
**Presentation:**
* **10 mg lyophilised powder vial** (reconstitute with 5 mL sterile water → 2 mg/mL).
* **Supplied as bromide salt** (vecuronium bromide).
**Pharmacokinetics:**
* **Onset:** 2–3 min.
* **Peak:** 3–5 min.
* **Duration:** 25–40 min (intermediate-acting).
* **Elimination half-life:** 60–90 min.
* **Metabolism:** hepatic deacetylation → **3-desacetyl-vecuronium (active metabolite)**.
* **Excretion:** biliary (75%), renal (25%).
**Disadvantages (from PK):**
* **Prolonged action** in hepatic/renal impairment due to accumulation.
* **Slower onset** than rocuronium or suxamethonium.
* **No vagolysis or histamine release** → may not counteract opioid/volatile-induced bradycardia.
---
# 3) Practical dosing
## A. Anaesthesia (intubation & maintenance)
* **Intubation dose:** **0.08–0.1 mg/kg IV** (≈ 6–7 × ED95).
* *Onset:* 2–3 min → slower than suxamethonium/rocuronium.
* *Duration:* 25–40 min.
* **Maintenance dose:** **0.01–0.02 mg/kg IV** bolus as required or **infusion 1–2 mcg/kg/min**.
* **Priming dose (optional):** 0.01 mg/kg (10% of intubation dose) 3–5 min before induction for faster onset.
## B. ICU (prolonged ventilation / paralysis)
* **Initial bolus:** 0.1 mg/kg.
* **Maintenance infusion:** **0.8–1.7 mcg/kg/min**, titrated to Train-of-Four (TOF 1–2 twitches).
* Avoid prolonged infusions >24–48 h if possible → **critical illness myopathy/neuropathy** risk, esp. with corticosteroids.
**Compatibility:** dilute in 0.9% saline or 5% dextrose; stable for 24 h at room temperature.
---
# 4) Special populations — dosing cautions
### Pregnancy
* Crosses placenta minimally; used safely for caesarean section (no fetal depression).
* Slightly prolonged effect postpartum due to hormonal changes.
### Lactation
* Minimal transfer to breast milk; safe after emergence.
### Hepatic impairment
* **Prolonged duration** due to decreased metabolism and biliary excretion → reduce maintenance dose, monitor TOF closely.
### Renal impairment
* Accumulation of active metabolite (3-desacetyl-vecuronium) → **prolonged paralysis**.
* Use lower infusion rates or prefer **atracurium/cisatracurium** (Hoffmann elimination).
### Obesity
* Dose based on **Ideal Body Weight (IBW)** to avoid overdosing.
### Paediatrics
* **Dose:** 0.1 mg/kg IV (same ED95); shorter duration due to higher clearance in young children.
* Neonates more sensitive → reduce dose (0.05–0.08 mg/kg).
---
# 5) Drug interactions (clinically key)
**Potentiation (enhanced block):**
* **Volatile anaesthetics** (esp. sevo/des/iso) – augment NMJ blockade.
* **Aminoglycosides, clindamycin, tetracyclines** – inhibit ACh release.
* **MgSO₄, Ca²⁺ channel blockers, local anaesthetics, lithium** – depress ACh release/excitation–contraction coupling.
* **Hypothermia, acidosis, hypokalaemia, hypocalcaemia** – prolong paralysis.
**Antagonism (reduced effect):**
* **Chronic phenytoin or carbamazepine** use → enzyme induction, resistance to block.
* **Burn injury, hemiplegia/paraplegia, myasthenia gravis remission** → receptor upregulation, increased resistance.
**Reversal interactions:**
* **Neostigmine** (with atropine/glycopyrrolate) → restores ACh levels; only once TOF ≥2.
* **Sugammadex** (specific for aminosteroids: vecuronium, rocuronium) → rapid encapsulation and reversal.
---
# 6) Significant complications & management
| Complication | Mechanism / Features | Management |
| --------------------------------------- | ------------------------------------------------------------------ | -------------------------------------------------------------------------------------------------- |
| **Prolonged neuromuscular block** | Accumulation or potentiation (renal/hepatic failure, drug synergy) | Neuromuscular monitoring; reversal with **neostigmine** or **sugammadex**; supportive ventilation. |
| **Critical illness myopathy** | Prolonged infusion + corticosteroids | Minimise duration; avoid unnecessary paralysis; physiotherapy post-ICU. |
| **Residual paralysis / awareness risk** | Inadequate reversal | TOF monitoring, reversal agent, clinical check (head lift, tidal volume). |
| **Anaphylaxis (rare)** | IgE-mediated | Stop drug; treat with **adrenaline**, fluids, airway management. |
---
## 7) Monitoring
* **Neuromuscular monitoring (TOF):**
* 4:0 = full recovery
* 4:1–2 = adequate for reversal
* 1–2 twitches = ideal for surgery
* 0 twitches = deep block (avoid prolonged period in ICU)
---
## Pocket viva line
*Vecuronium is an **aminosteroid non-depolarising NMJ blocker** causing **competitive antagonism at nicotinic ACh receptors**. It produces smooth paralysis with stable haemodynamics, **no histamine release**, and is **reversible with neostigmine or sugammadex**.
Dose **0.08–0.1 mg/kg IV** for intubation, **0.01–0.02 mg/kg** for maintenance, or **1 mcg/kg/min** infusion in ICU. Duration **25–40 min**, prolonged in hepatic/renal dysfunction.*
---
Would you like me to continue next with **Rocuronium** (fast-onset aminosteroid and suxamethonium alternative) or **Atracurium** (benzylisoquinolinium, Hofmann-eliminated, ICU-friendly)?
No comments:
Post a Comment